Anonymous (2026). Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.. Circulation.
Anonymous. Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.. Circulation. 2026; PMID: 42183757
Anonymous. Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.[J]. Circulation. 2026.
@article{paper2026,
author = {Anonymous},
title = {Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.},
journal = {Circulation},
year = {2026},
note = {PMID: 42183757},
}
TY - JOUR AU - Anonymous TI - Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial. T2 - Circulation PY - 2026 AN - PMID:42183757 ER -
Lipoprotein(a) [Lp(a)] is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher risk patients who derive more benefit from evolocumab is not established in a population without prior myocardial infarction (MI) or stroke.